Premium
Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) in radical cystectomy patients
Author(s) -
Bahnson Robert R.,
Ernstoff Marc S.,
Miller Ralph J.,
O'Donnell Walter F.
Publication year - 1990
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930450303
Subject(s) - medicine , cystectomy , vinblastine , urology , toxicity , chemotherapy , cisplatin , doxorubicin , adjuvant , bladder cancer , methotrexate , surgery , oncology , cancer
A reduction in the toxicity of M‐VAC chemotherapy has been postulated for patients who receive these drugs prior to radical cystectomy for muscle invasive bladder carcinoma: A review of the toxicity and patient dropout rates from a group of 9 patients who received neoadjuvant M‐VAC was little different from 9 patients who were treated with M‐VAC after radical cystectomy. This similarity suggests that preoperative M‐VAC should not be favored on the basis of reduced patient morbidity.